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ABSTRACT
Objective: Acute exacerbations (AE) are a contributing cause of worsening chronic obstructive pulmonary disease (COPD) in conditions of lung 
function decline, quality of liveliness, and natural selection. The most important concept of this article is the positive correlation between the serum 
magnesium levels at worsening of symptoms and annual number of episodes.
Methods: Blood samples from the patients who are diagnosed with AE of COPD will be collected and evaluated for serum magnesium levels and 
serum fibrinogen levels. Low serum magnesium is a modifiable risk factor. It is generally believed that, due to its bronchodilating effect, a decreased 
level of magnesium increases COPD exacerbations. The best blood biomarker for the systemic tenderness in COPD used here is plasma fibrinogen. 
Those with the increased fibrinogen levels had induced the higher admission rates with COPD. This clause deals with the association of both serum 
magnesium and serum fibrinogen levels with AE-COPD.
Results: The serum magnesium levels on discharge in stable type were found to be 2.3±0.27, and in exacerbation, it was found to be 1.56±0.37. 
Moreover, on discharge, serum fibrinogen levels in stable type were found to be 1.64±0.32, and in exacerbation, it was found to be 2.18±0.40.
Conclusion: Low serum magnesium levels may be a complication for AE of COPD. High serum fibrinogen levels may be a complication for AE of COPD. 
We hereby recommend regular screening of serum magnesium and serum fibrinogen levels for all the COPD patients to predict and prevent AE.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is determined by 
lung disease causing breathing difficulties due to the penetration 
of small airways with inflammatory cells and breathlessness [1,2]. 
Exacerbations are worsening of the symptoms. Acute exacerbation 
(AE) of pulmonary disease represents a central moment in the 
series of COPD. The relationship between AECOPD and decrease 
in health status and lung function is easily accepted [3,4]. These 
cases take up around 50% of the direct cost for COPD [5]. AE that 
adjusts the quality of life, declines in respiratory functions, and 
increases the economic costs may occur during the course of stable 
COPD [6,7]. The acute worsening of respiratory symptoms that 
were beyond normal daily variations of symptoms is termed as 
COPD exacerbation.
Serum magnesium
Serum magnesium is required in such major uses as bronchodilation and 
contraction in respiratory tract smooth muscles, mast cell stabilization, 
neurohumoral mediator release, and mucociliary clearance [8]. 
Magnesium is thought to possess a protective effect against chronic 
respiratory tract diseases. It has been proposed that insufficient 
magnesium intake through diet may lead to the development of asthma 
and COPD [9,10].
It is one of the major intracellular cations. Normal value: 0.7–1 
mmol/L (1.5–2 mEq/L; 1.7–2.4 mg/DL) [11,12] Critical value: <1 and 
>4.9 mg/DL [12].
Serum fibrinogen
Serum fibrinogen has come out as the best biomarker in this pulmonary 
disease and is currently being considered for alteration as a drug 
development tool by the USFDA and the EMA [13,14].
However, the plasma range of fibrinogen in patients with obstructive 
breathing disorder has been probed, and in the restrictive pulmonary 
disorder such as pulmonary fibrosis, the values are not yet well defined 
in these patients [15-18]. Normal fibrinogen ranges between 1.5 and 
3.5 g/l.
METHODS
The survey was placed out in General Medicine Department of ESI 
Hospital, Ayanavaram, with the sample size random sampling of a 
population of 200 persons with a confidence interval of 95% and the 
sample size was found to be 132 patients. The duration of the study 
was September 2017-April 2018. The study design was a prospective 
observational study. The study procedure followed was ask the patient 
to make the arm relaxed and point the vein. The needle should form a 
15 to 30° angle with the arm surface. 5 ml of blood sample is picked up. 
Blood samples from the patients who are diagnosed with AE of COPD 
will be collected and evaluated for serum magnesium levels and serum 
fibrinogen levels.
Study instruments
Conventional auto analyzer equipment and class assay were used.
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PATIENT SELECTION
Inclusion criteria
The following criteria were included in the study:
1. Patients above 18 years of age
2. Patients identified with AE of COPD.
Exclusion criteria
The following criteria were excluded from the study:
1. Pregnant and nursing women.
2. Patient with lung carcinoma.
3. Palliative patients.
4. Patients with coagulation disorders.
RESULTS
Table 1 shows that, among 140 enrolled participants, 90 (64.2) were 
male and 50 (35.7) were female.
Table 2 shows that 7 (5%) of the participants belonged to the age group 
of 18–35 years, 27 (19.2%) of the participants belonged to the age 
group 36–50 years, 56 (40%) of the participants belonged to the age 
group 51–65 years, and 50 (35.7%) of the participants belonged to the 
age group 66–80 years, respectively
Table 3 discusses about the comorbidity condition among the patients.
Hypertension is seen among 32.8% of the total patients, diabetes 
mellitus is seen among 58.5% of patients, bronchial asthma is seen 
among 4.2% of patients, cardiovascular disease is seen among 14.2% of 
patients, and rheumatoid arthritis is seen among 5% of patients.
No patients were recorded positive test for HIV among patients.
Table 4 shows that the total number of patients’ stable was found to be 
22 (15.7%) and exacerbation was found to be 118 (84.2%).
Table 5 shows that stable smoking status among smoker was found to 
be 17, ex-smoker was 03, and non-smoker was 02.
The exacerbation smoking status among smoker was found to be 69, 
ex-smoker was 31, and non-smoker was 18.
*p value in exacerbation was found to be significant with 95% level of 
significance.
Table 6 shows about the number of admission per year in hospital with 
COPD.
Table 7 discusses about the Modified Medical Research Council (MMRC) 
grade scale; with scores of 1, number of patients were 04 (2.8%); with 
score of 2, numberof patients were 26 (18.5%); with score of 3, number 
of patients were 50 (35.7%); and with score of 4, total number of 
patients were 60 (42.8).
Table 8 shows that serum magnesium levels on admission in stable type 
were found to be 2.2±0.37, and in exacerbation, it was found to be 1.0±0.27, 
*p<0.05 which is statistically significant.
Table 9 shows that serum magnesium levels on discharge in stable type 
were found to be 2.3±0.27, and in exacerbation, it was found to be 1.56±0.37, 
*p<0.05 which is statistically significant.
Table 1: Gender distribution
S. No. Gender Number of patients n=140 (%) (%)
1. Male 90 (64.2) 64.2
2. Female 50 (35.7) 35.7
Table 2: Age distribution
S. No. Age group (years) Number of patients n=140 (%)
1. 18–35 07 (5)
2. 36–50 27 (19.2)
3. 51–65 56 (40)
4. 66–80 50 (35.7)
Table 3: Comorbidities
S. No. Comorbidity Number of patients n=140 (%)
1. HTN 46 (32.8)
2. DM 82 (58.5)
3. BA 06 (04.2)
4. CVD 20 (14.2)
5. HIV 00 (0)
6. RA 07 (05)
CVD: Cardiovascular disease, HTN: Hypertension
Table 4: Types of COPD
S. No. Type Number of patients n=140 (%)
1. Stable 22 (15.7)
2. Exacerbation 118 (84.2)
COPD: Chronic obstructive pulmonary disease
Table 5: Smoking status
S.No. Type Smoker Ex‑smoker Non‑smoker p value
1. Stable 17 03 02 0.71
2. Exacerbation 69 31 18 0.04*
Table 6: Number of admission per year
S.No. Number of admissions Number of patients (%)
1. 0 06 (4.2)
2. 1 34 (24.2)
3. 2–3 90 (64.2)
4. >3 10 (7.1)
Table 7: MMRC dyspnea grade scale
S. No. MMRC grade Number of patients (%) Percentage (%)
1. 0 00 (00) 00
2. 1 04 (02.8) 02.8
3. 2 26 (18.5) 18.5
4. 3 50 (35.7) 35.7
5. 4 60 (42.8) 42.8
MMRC: Modified Medical Research Council
Table 8: Serum magnesium levels (admission)
S.No. Type Serum magnesium 
levels (mEq/L)
p value
1. Stable (22) 2.2±0.37 0.0041*
2. Exacerbation (118) 1.0±0.27
All values are mean±SEM
Table 9: Serum magnesium levels (discharge)
S. No. Type Serum magnesium 
levels (mEq/L)
p value
1. Stable (22) 2.3±0.27 0.0271*
2. Exacerbation (118) 1.56±0.37
All values are mean±SEM
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Table 10 shows that serum fibrinogen levels on admission in stable 
type were found to be 1.76±0.32, and in exacerbation, it was found to 
be 3.16±0.39.
Moreover, on discharge, serum fibrinogen levels in stable type was 
found to be 1.64±0.32, and in exacerbation, it was found to be 2.18±0.40, 
*p<0.05 which is statistically significant.
DISCUSSION
COPD is due to the worsening of symptoms that is commonly defined 
as an exacerbation. Major prominence in the treatment of patients with 
COPD must be on the continuation of stability. There is an increasing 
awareness on the role of magnesium in pulmonary disease. Many 
patients with elevated Serum Magnesium were subjected for frequent 
hospitalizations in COPD [19].
The most significant finding of this work is the positive correlation 
between serum magnesium levels during AE and annual number of 
COPD-AE. The number of attacks increased in association with serum 
Mg levels. This is a potentially important finding.
Serum magnesium levels were assessed in the AE period for admission 
to hospital. Magnesium levels in the stable period were not tested. 
Magnesium levels could not, consequently, be compared between the 
stable and COPD-AE patients.
Therefore, the serum ionic magnesium level was found significantly 
lower in COPD cases, either in the exacerbation or in static state in 
comparison to healthy subjects; however, the diminution of serum 
ionic magnesium in subjects of AE of COPD was significantly lower 
than stable COPD subjects. It was also likely noted that the dyspnea 
was more prominent on the MMRC scale in subjects admitted with AE 
of COPD.
Hypomagnesemia was found as an important indicator in precipitation 
of AE of COPD by enhancing the episode of bronchoconstriction, and 
hence, evaluation of serum ionized magnesium must be retained in 
the routine panel of investigation to detect its disturbance in the early 
stage of worsening of symptoms to head off the morbidity as well as 
mortality in acutely ill COPD patients. Moreover, it can also be utilized 
as a prognostic indicator during ICU admission [21-23].
Fibrinogen is the best blood biomarker and also higher in individuals 
with metabolic syndrome. This indicates that fibrinogen may be a major 
contributor in the development of COPD comorbidities [20].
CONCLUSION
Our study revealed that there is a definite relationship between serum 
fibrinogen and serum magnesium levels with the AE-COPD.
• Low serum magnesium levels may be a complication for AE of COPD.
• High serum fibrinogen levels may be a complication for AE of COPD.
The treatment given to the patient for COPD must be given along with 
the regular checking of serum magnesium and serum fibrinogen levels. 
The importance of those serum levels must be educated to them for 
better treatment.
We hereby recommend regular screening of serum magnesium and serum 
fibrinogen levels for all the COPD patients to predict and prevent AE.
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